Utrophin increase in muscle cells after transcriptional adaptation normalises cell function in Duchenne muscular dystrophy Duchenne muscular dystrophy (DMD) is a rare hereditary disease that is ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Most children with Duchenne muscular dystrophy will need a wheelchair to ... Muscle weakness in the shoulders, upper arms, upper back, and lower legs Difficulty raising the arms or lifting objects ...

Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene, leading to muscle degeneration. Current treatments focus on maintaining muscle function, with emerging gene ...

Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...

Duchenne muscular dystrophy (DMD) is a genetic disorder that ... Early symptoms of muscle weakness begin in the arms and legs ...

Evan McMenamin said his brother Travis, "never lets it get him down" despite the "incredible challenges" he faces ...

Duchenne Muscular Dystrophy affects around 1 in 3500 male ... and it makes me feel sad. "My legs hurt and ache every day. "It's horrible." Lisa added, "Alfie's struggles and appointments take ...

Without functional dystrophin to support muscle strength and stability, muscle fibers are easily damaged. Duchenne muscular dystrophy results from mutations in the DMD gene that encodes the dystrophin ...

Duchenne Muscular Dystrophy (DMD) is a rare progressive disorder. People with DMD are missing muscle-protecting protein. This is due to a fault in the gene producing dystrophin. Muscles to become ...

Vamorolone is recommended, within its marketing authorisation, as an option for treating Duchenne muscular dystrophy (DMD) in people 4 years and over. Vamorolone is only recommended if the company ...

Italfarmaco's marketing application for HDAC inhibitor givinostat as a treatment for Duchenne muscular dystrophy (DMD) has been accepted by the EMA, setting up an approval decision in 2024.